ArticleClinical kidney journal2020
Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort.
Article in Clinical kidney journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Outcomes of atrial fibrillation in patients with COVID-19 pneumonia: A systematic review and meta-analysis.The American journal of emergency medicine · 2021Pooled it
- Cardiac biomarkers and COVID-19: A systematic review and meta-analysis.Journal of infection and public health · 2021Pooled it
- A meta-analysis on the risk factors adjusted association between cardiovascular disease and COVID-19 severity.BMC public health · 2021Pooled it
- Meta-Analysis of Atrial Fibrillation in Patients With COVID-19.The American journal of cardiology · 2021Pooled it
- Gastrointestinal Manifestation and In-hospital Mortality among End-Stage Renal Disease Patients with COVID-19: A Single-center Retrospective Cohort Study.Acta medica Philippina · 2025Article
- Incorporation of Chest Computed Tomography Quantification to Predict Outcomes for Patients on Hemodialysis with COVID-19.Kidney diseases (Basel, Switzerland) · 2024Article
- A multicenter study of severity and prognosis of symptomatic COVID-19 in end-stage renal disease and non-dialysis patients in East of Iran.Immunity, inflammation and disease · 2024Article
- Predictors of Mortality among End-Stage Renal Disease Patients with COVID-19 Admitted in a Philippine Tertiary Government Hospital: A Retrospective Cohort Study.Acta medica Philippina · 2024Article
- Clinical manifestations of COVID-19 infection in dialysis patients and protective effect of COVID-19 vaccine.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Review
- Humoral response to vaccination against SARS-CoV-2 in patients undergoing maintenance hemodialysis.Medicina clinica (English ed.) · 2023Article
- Sex differences in COVID-19 symptoms and outcomes in people with kidney failure treated with dialysis: a prospective cohort study.Journal of nephrology · 2023Observational
- COVID - 19 in two dialysis centers situated in two neighbouring states of the Western Balkans.BMC nephrology · 2023Observational
- Hemodialysis-Associated Immune Dysregulation in SARS-CoV-2-Infected End-Stage Renal Disease Patients.International journal of molecular sciences · 2023Article
- Capacity planning for effective cohorting of hemodialysis patients during the coronavirus pandemic: A case study.European journal of operational research · 2023Article
- Longitudinal Cluster Analysis of Hemodialysis Patients with COVID-19 in the Pre-Vaccination Era.Life (Basel, Switzerland) · 2022Article
- Vaccination against SARS-CoV-2 in Haemodialysis Patients: Spike's Ab Response and the Influence of BMI and Age.International journal of environmental research and public health · 2022Article
- Presence of specific SARS-COV2 antibodies in hemodialysis patients and their caregivers after the first wave of COVID-19.Scientific reports · 2022Article
- Cardiovascular complications after COVID-19 in chronic kidney disease, dialysis and kidney transplant patients.International urology and nephrology · 2022Review
- Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study.Journal of clinical medicine · 2022Article
- Article
Corrections and comments
- Comment on
Authors and funding
30 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronavirus disease 2019 (COVID-19) is an emerging infectious disease, related to severe acute respiratory syndrome coronavirus 2 infection. Few data are available in patients with end-stage renal disease (ESRD).
methodsWe conducted an observational cohort study of COVID-19 patients at 11 dialysis centres in two distinct districts of France to examine the epidemiological and clinical characteristics of COVID-19 in this population, and to determine risk factors of disease severity (defined as a composite outcome including intensive care unit admission or death) and mortality.
resultsAmong the 2336 patients enrolled, 5.5% had confirmed COVID-19 diagnosis. Of the 122 patients with a follow-up superior to 28 days, 37% reached the composite outcome and 28% died. Multivariate analysis showed that oxygen therapy on diagnosis and a decrease in lymphocyte count were independent risk factors associated with disease severity and with mortality. Chronic use of angiotensin II receptor blockers (ARBs) (18% of patients) was associated with a protective effect on mortality. Treatment with azithromycin and hydroxychloroquine (AZT/HCQ) (46% of patients) were not associated with the composite outcome and with death in univariate and multivariate analyses.
conclusionsCOVID-19 is a severe disease with poor prognosis in patients with ESRD. Usual treatment with ARBs seems to be protective of critical evolution and mortality. There is no evidence of clinical benefit with the combination of AZT/HCQ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.